Lagarde Sebastián, María de Pulido Ortega, Federico Rubio García, Rafael
Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. [artículo - PloS one, 2013 - 8(7):e69493.
Formato Vancouver:
Pérez-Valero I, González-Baeza A, Estébanez M, Montes-Ramírez ML, Bayón C, Pulido F et al. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One.
2013 Jul 25;8(7):e69493.
PMID: 23936029
Contiene 32 referencias
BACKGROUND: In patients who remain virologically suppressed in plasma with triple-drug ART a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is unknown if protease inhibitor monotherapy is associated to a higher rate of neurocognitive impairment.
Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. [artículo - PloS one, 2013 - 8(7):e69493.
Formato Vancouver:
Pérez-Valero I, González-Baeza A, Estébanez M, Montes-Ramírez ML, Bayón C, Pulido F et al. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One.
2013 Jul 25;8(7):e69493.
PMID: 23936029
Contiene 32 referencias
BACKGROUND: In patients who remain virologically suppressed in plasma with triple-drug ART a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is unknown if protease inhibitor monotherapy is associated to a higher rate of neurocognitive impairment.
